Cancer Network Staff

Initial phase 2 SURF302 data show a 79% ORR with 60 mg once-daily oral dabogratinib in FGFR3-altered low-grade intermediate-risk NMIBC.

Adding atezolizumab to neoadjuvant chemotherapy did not significantly improve EFS in early TNBC, but node-positive and high-TIL subgroups showed benefit.

Data at SOHO 2026 show how FLT3 inhibitors and venetoclax-based triplets have reshaped induction, consolidation, and maintenance therapy in FLT3-mutated AML.

The first patient has been dosed in a phase 2 trial evaluating paxalisib plus gemcitabine in children and young adults with recurrent atypical teratoid/rhabdoid tumor.

The interim 3-year OS rates were 71.2% with OST-HER2 vs 45.8% in historical controls in a phase 2b trial of fully resected, pulmonary metastatic osteosarcoma.

Data from the phase 3 DeLLphi-305 trial also showed meaningful improvements in progression-free survival and responses with durvalumab/tarlatamab in SCLC.

In a phase 1/2 study, daraxonrasib produced objective responses in more than 30% of patients with previously treated RAS-mutant NSCLC.

Interim phase 2 data show INBRX-106 plus pembrolizumab nearly doubled response rates and extended survival vs pembrolizumab alone in head and neck cancer.

The FDA withdrew accelerated approval for adagrasib/cetuximab in KRAS G12C-mutated colorectal cancer after the KRYSTAL-10 trial failed to improve survival.

A GDNS protocol did not significantly reduce loss of ASMI compared with usual care during chemoradiotherapy following esophagectomy in esophageal cancer.

The phase 3 TAK-226-3001 trial will evaluate elritercept vs epoetin alfa for anemia in lower-risk myelodysplastic syndromes.

Data from the phase 2 PARADIGM trial may support the use of less toxic, more gentle therapies for patients with acute myeloid leukemia.

Global Burden of Disease data showed alcohol-attributable cancer deaths in the US doubled from 1990 to 2023, with liver cancer showing the steepest rise.

“Far and away, a unified electronic health record is the single use case that could benefit both patients and physicians most, and AI has the potential to help us achieve that,” said Margarita Racsa, MD, MPH.

FDA approved camizestrant for HR+/HER2– advanced breast cancer with emerging ESR1 mutations based on data from the SERENA-6 trial.

Full results from the phase 3 CERVINO trial assessing etentamig in relapsed/refractory multiple myeloma will be shared at the 23rd IMS Annual Meeting.

How do we implement AI in a way that serves patients? Expert radiation oncologists discuss the crucial question.

Experts in breast cancer discussed final CAPItello-291 overall survival data and their implications for capivasertib plus fulvestrant.

Blinded survival data from the phase 3 LIVERATION trial of namodenoson in advanced hepatocellular carcinoma appear longer than anticipated.

According to Margarita Racsa, MD, MPH, patients coming in with AI-informed insights can be a double-edged sword for clinicians.

Patients with nonmetastatic prostate cancer in the highest quintile of postdiagnosis saturated fat consumption showed a 24% greater risk of all-cause mortality vs the lowest quintile.

Neil Iyengar, MD; Rebecca Shatsky, MD; and Carol Tweed, MD, discuss camizestrant and SERENA-6 ctDNA monitoring for ESR1-mutant HR+/HER2– breast cancer.

The European Commission has approved T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer based on DESTINY-Breast09.

Updated HERIZON-GEA-01 survival data show zanidatamab-based regimens outperformed trastuzumab/chemotherapy in first-line HER2-positive advanced GEA.

The regulatory decision for JBS-003 is intended to help guide personalized radiation de-escalation in patients with HPV-positive oropharyngeal cancer.

AI is intended to assist physicians, giving them more time for interpersonal engagement with patients, according to Nevine Hanna, MD, MPH, FACRO, DABR.

Updated interim PYNNACLE trial data showed a 46% response rate with rezatapopt monotherapy in platinum-resistant/refractory ovarian cancer.

Tumor-informed ctDNA testing with the Signatera assay outperformed standard PET/CT imaging across B- and T-cell lymphoma subtypes.

Data from the phase 3 SENTRY trial support the supplemental new drug application for selinexor plus ruxolitinib in patients with myelofibrosis.

ASCO’s updated breast cancer follow-up guideline replaces routine, one-size-fits-all surveillance with a 3-tier, risk-based model.